Citius Oncology, Inc. · NASDAQ:CTOR
Citius Oncology — Investor Presentation (October 2025)
19 slides from Citius Oncology's investor presentation, Oct 23, 2025
Slide 1: Corporate Overview October 2025
CORPORATE OVERVIEW NASDAQ: CTOR OCTOBER 2025 Exhibit 99.1
Slide 2: Forward Looking Language
FORWARD LOOKING LANGUAGE This presentation has been prepared by Citius Oncology, Inc . (the “Company”) for informational purposes only and not for any other purpose . Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or a
Slide 3: About Citius Oncology, Inc.
ABOUT CITIUS ONCOLOGY, INC. Biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies • Lead product, LYMPHIR , FDA approved August 2024 • Orphan Indication: treatment of adult patients with relapsed or refractory Stage I - III cutaneous T - cell lymp
Slide 4: Citius Is Preparing to Launch LYMPHIR in Q4 2025
CITIUS IS PREPARING TO LAUNCH LYMPHIR IN Q4 2025 NASDAQ: CTOR | 4 Commercial launch readiness nearing completion through disciplined financial strategy Citius has invested ~$90 million in LYMPHIR to date $40M $43+M $5M Upfront purchase Development and precommercial efforts Spinout to form Citius Onc
Slide 5: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM NASDAQ: CTOR | 5 Shared management services agreement with Citius Pharmaceuticals mitigates execution risk, maximizes capital efficiency and leverages industry expertise LEONARD MAZUR CHAIRMAN & CEO JAIME BARTUSHAK EVP, CFO & CBO DR. MYRON CZUCZMAN EVP, CHIEF MEDICAL OFFI
Slide 6: What Is Cutaneous T-Cell Lymphoma (CTCL)?
WHAT IS CUTANEOUS T - CELL LYMPHOMA (CTCL)? NASDAQ: CTOR | 6 Considered to be incurable, CTCL is a Subgroup of Non - Hodgkin Lymphomas (NHL) that can be Indolent or Aggressive and is Driven by Malignant T Cells CTCL is a general term for T - cell lymphoma that involves the skin, but may also involve
Slide 7: CTCL Patients Have a High Disease Burden
NASDAQ: CTOR | 7 CTCL PATIENTS HAVE A HIGH DISEASE BURDEN T1 T4 Sézary cell T2 T3 Zackheim. J Am Acad Dermatol. 1999;40:418. Slide credit: clinicaloptions.com
Slide 8: Differentiated Mechanism of Action (MOA)
NASDAQ: CTOR | 8 DIFFERENTIATED MECHANISM OF ACTION (MOA) LYMPHIR targets the IL - 2 receptor, working both as a targeted therapy against malignant T - cells AND as an immunotherapy against Tregs IL - 2 receptor offers a unique treatment opportunity in CTCL Malignant T - cells and Tregs share a comm
Slide 9: Compelling Clinical Data
NASDAQ: CTOR | 9 COMPELLING CLINICAL DATA LYMPHIR addresses CTCL’s heavy Quality of Life burden 1. Objective Response is Complete Response and Partial Response according to the ISCL/EORTC Global Response Score. 2. In the Primary Efficacy Analysis set, 84.4% (54/64) of skin evaluable subjects had a d
Slide 10: Demonstrated Safety
DEMONSTRATED SAFETY NASDAQ: CTOR | 10 Overall, LYMPHIR was well - tolerated with the use of pre - medications, close patient monitoring, and prompt initiation of supportive measures and drug management • No evidence of cumulative toxicity • Most patients experienced grade 1/2 treatment emergent adve
Slide 11: Opportunities for Growth Beyond CTCL
OPPORTUNITIES FOR GROWTH BEYOND CTCL • University of Pittsburgh: an investigator - initiated trial is underway to evaluate LYMPHIR for potential use as an immuno - oncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) • Encouraging prelimi
Slide 12: LYMPHIR Is Competitively Positioned
LYMPHIR IS COMPETITIVELY POSITIONED Clinical profile and market dynamics supports market entry • Differentiated MOA targeting the IL - 2 receptor reinforces rationale for inclusion among the current core therapeutic options in the U.S. market • CTCL treatments are non - curative , often have a limit
Slide 13: Competitive Landscape: Why Choose LYMPHIR?
COMPETITIVE LANDSCAPE: WHY CHOOSE LYMPHIR? Today’s CTCL treatments are non - curative LYMPHIR excels where current therapies are limited • Requires CD30+ biomarker • Peripheral neuropathy may limit use • Most effective in SS subsegment of CTCL (<5%) • Acts on blood disease rather than skin disease •
Slide 14: Concentrated Prescriber Base
CONCENTRATED PRESCRIBER BASE NASDAQ: CTOR | 14 10% of Providers (Physicians) Treat ≥3 Patients 90 17 7 15 12 0 10 20 30 40 50 60 70 Number of Accounts 80 90 100 20 - 40 41 - 60 61 - 80 81 - 120 121 - 475 Number of Patients Accounts by Number of Diagnosed Patients Source: IQVIA Medical (Dx) & Pharmac
Slide 15: Patient and HCPs Clustered Near Major Cancer Centers
PATIENT AND HCPS CLUSTERED NEAR MAJOR CANCER CENTERS • Concentration of providers and accounts allows for a focused field force approach (~25 reps) • AI - driven trigger system will direct the field force to optimize opportunities with providers and patients 15 60% of CTCL patients are concentrated
Slide 16: Distribution Readiness and Channel Access
DISTRIBUTION READINESS AND CHANNEL ACCESS Patient - Centric Distribution Strategy aims to promote timely product availability for eligible CTCL patients across all care settings, reinforcing Citius’ commitment to access • Nationwide U.S. distribution network established • All major distribution agre
Slide 17: Focused Product Launch
FOCUSED PRODUCT LAUNCH NASDAQ: CTOR | 17 Solid foundation supporting potential market share ramp in Year 1 with targeted salesforce 1. JAMA Oncology. 2022 Sep 1;8(11):1690 – 1692. doi: 10.1001/jamaoncol.2022.3236 Patients • We plan to target the cohort of U.S. patients with relapsed or refractory CT
Slide 18: Multi-Layered Protection: Barriers to Entry
NASDAQ: CTOR | 18 MULTI - LAYERED PROTECTION: BARRIERS TO ENTRY 12 years of BLA exclusivity Orphan Drug Exclusivity (7 years) ODD designation granted for CTCL and PTCL (CTCL exclusivity determined upon BLA review) Complex Proprietary Manufacturing Process trade secret 2 Patents Pending LYMPHIR use a
Slide 19: Why CTOR? Why Now?
WHY CTOR? WHY NOW? LYMPHIR is poised for successful launch with potential upside opportunities beyond CTCL • LYMPHIR is an approved therapy in a rare indication with no curative therapies • Estimated $400M+ addressable U.S. market1 with potential upside potential driven by expanded indications, immu
Citius Oncology — Investor Presentation (October 2025) on 6ix